{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:28:14Z","timestamp":1788917294675,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.urolonc.2019.02.004","type":"journal-article","created":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T16:37:17Z","timestamp":1551717437000},"page":"430-436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7864-408X","authenticated-orcid":false,"given":"Beat","family":"Foerster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1625-1077","authenticated-orcid":false,"given":"David","family":"D'Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6603-6319","authenticated-orcid":false,"given":"Mohammad","family":"Abufaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Broenimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre I.","family":"Karakiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth P.","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6627-6179","authenticated-orcid":false,"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2019.02.004_bib0001","article-title":"Cancer statistics, 2018","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0002","first-page":"35","article-title":"Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)","author":"Soria","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0003","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.eururo.2014.08.003","article-title":"Conditional survival after radical nephroureterectomy for upper tract carcinoma","volume":"67","author":"Ploussard","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0004","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2012.02.030","article-title":"Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature","volume":"62","author":"Lughezzani","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0005","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.eururo.2012.01.021","article-title":"Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma","volume":"61","author":"Cha","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0006","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","article-title":"European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 Update","volume":"73","author":"Roupr\u00eat","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0007","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.eururo.2016.07.014","article-title":"oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel","volume":"70","author":"Seisen","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0008","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.eururo.2012.03.051","article-title":"Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis","volume":"62","author":"Sun","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0009","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1464-410X.2010.09899.x","article-title":"Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma","volume":"108","author":"Messer","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1464-410X.2011.10288.x","article-title":"Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma","volume":"109","author":"Favaretto","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0011","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.eururo.2009.07.002","article-title":"Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy","volume":"57","author":"Raman","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0012","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1464-410X.2008.08003.x","article-title":"Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients","volume":"103","author":"Remzi","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0013","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.eururo.2011.09.017","article-title":"The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy","volume":"61","author":"Chromecki","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0014","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrurol.2015.24","article-title":"Risk-adapted strategy for the kidney-sparing management of upper tract tumours","volume":"12","author":"Seisen","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0015","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1464-410X.2012.11068.x","article-title":"Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review","volume":"110","author":"Cutress","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0016","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.urology.2008.06.026","article-title":"A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Gu\u00e9rin therapy?","volume":"73","author":"Rastinehad","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0017","first-page":"272","article-title":"Serial retrograde instillations of sustained release formulation of mitomycin C to the upper urinary tract of the Yorkshire swine using a thermosensitive polymer: Safety and feasibility","volume":"35","author":"Donin","year":"2017","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0018","doi-asserted-by":"crossref","unstructured":"Lifshitz D., Meiron M., Konorty M., Schoenberg M. Hydrogel based drug retention system for the treatment of upper tract urothelial carcinoma vol. 13. 2014. doi:10.1016\/S1569-9056(14)60027-0.","DOI":"10.1016\/S1569-9056(14)60027-0"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0019","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijpharm.2016.08.061","article-title":"Drug-eluting biodegradable ureteral stent: new approach for urothelial tumors of upper urinary tract cancer","volume":"513","author":"Barros","year":"2016","journal-title":"Int J Pharm"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0021","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/2049-3258-72-39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014","journal-title":"Arch Public Heal"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0022","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0023","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0022-5347(17)37897-7","article-title":"The management of transitional cell carcinoma in solitary renal units","volume":"146","author":"Schoenberg","year":"1991","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0024","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0022-5347(17)35473-3","article-title":"Technique of mitomycin C instillation in the treatment of upper urinary tract urothelial tumors","volume":"150","author":"Eastham","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0025","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0022-5347(01)65854-3","article-title":"Endourological treatment of upper tract urothelial carcinomas: analysis of a series of 59 tumors","volume":"156","author":"Mart\u00ednez-Pi\u00f1eiro","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0026","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/S0022-5347(01)68157-6","article-title":"Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma","volume":"158","author":"Keeley","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0027","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0022-5347(01)64015-1","article-title":"New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma","volume":"159","author":"Patel","year":"1998","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0028","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0022-5347(01)61765-8","article-title":"13-year experience with percutaneous management of upper tract transitional cell carcinoma","volume":"161","author":"Clark","year":"1999","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0029","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/01.ju.0000050242.68745.4d","article-title":"Percutaneous management of renal pelvic urothelial tumors: long-term followup","volume":"169","author":"Goel","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0030","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/01.ju.0000132128.79974.db","article-title":"Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup","volume":"172","author":"Palou","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0031","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1089\/end.2007.9969","article-title":"Setting a new standard for topical therapy of upper-tract transitional-cell carcinoma: BCG and Interferon-\u03b12B","volume":"21","author":"Katz","year":"2007","journal-title":"J Endourol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0032","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.eururo.2011.07.051","article-title":"Antegrade perfusion with bacillus Calmette-Gu\u00e9rin in patients with non-muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit?","volume":"60","author":"Giannarini","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0033","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0022-5347(17)36117-7","article-title":"Intrarenal bacillus Calmette-Guerin therapy for upper urinary tract carcinoma in situ","volume":"149","author":"Sharpe","year":"1993","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0034","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1046\/j.1464-410X.1996.09559.x","article-title":"Bacillus Calmette-Gu\u00e9rin perfusion therapy for carcinoma in situ of the upper urinary tract","volume":"77","author":"Yokogi","year":"1996","journal-title":"Br J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0035","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1046\/j.1464-410x.2000.00610.x","article-title":"Bacillus Calmette-Gu\u00e9rin instillation treatment for carcinoma in situ of the upper urinary tract","volume":"85","author":"Nishino","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0036","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1159\/000020365","article-title":"Bacillus Calmette-Gu\u00e9rin perfusion therapy for the treatment of transitional cell carcinoma in situ of the upper urinary tract","volume":"38","author":"Nonomura","year":"2000","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0037","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1464-410X.2001.02297.x","article-title":"Intrarenal bacillus Calmette-Gu\u00e9rin therapy for carcinoma in situ of the upper urinary tract: long-term follow-up and natural course in cases of failure","volume":"88","author":"Okubo","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0038","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0090-4295(01)01488-1","article-title":"Intravesical instillation of bacille Calmette-Gu\u00e9rin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double-pigtail catheter","volume":"59","author":"Irie","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0039","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1046\/j.1442-2042.2002.00551.x","article-title":"Clinical outcome of bacillus Calmette-Gu\u00e9rin perfusion therapy for carcinoma in situ of the upper urinary tract","volume":"9","author":"Miyake","year":"2002","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0040","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0022-5347(05)64454-0","article-title":"Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery","volume":"168","author":"Thalmann","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0041","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.urology.2004.01.046","article-title":"Long-term effects of bacille calmette-gu\u00e9rin perfusion therapy for treatment of transitional cell carcinoma in situ of upper urinary tract","volume":"63","author":"Hayashida","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0042","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1442-2042.2006.01312.x","article-title":"Long-term outcome of upper urinary tract carcinoma in situ: effectiveness of nephroureterectomy versus bacillus Calmette-Gu\u00e9rin therapy","volume":"13","author":"Kojima","year":"2006","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0043","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1089\/end.2012.0229","article-title":"Outcomes of intrarenal bacillus Calmette-Gu\u00e9rin\/Interferon-\u03b12B for biopsy-proven upper-tract carcinoma in situ","volume":"26","author":"Shapiro","year":"2012","journal-title":"J Endourol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0044","first-page":"261","article-title":"Treatment outcome of intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract","volume":"59","author":"Anan","year":"2013","journal-title":"Hinyokika Kiyo"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12032-018-1102-y","article-title":"Impact of bacillus Calmette-Gu\u00e9rin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy","volume":"35","author":"Horiguchi","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0046","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/07357907.2018.1430815","article-title":"Efficacy and tolerability of bacillus Calmette-Gu\u00e9rin therapy as the first-line therapy for upper urinary tract carcinoma in situ","volume":"36","author":"Tomisaki","year":"2018","journal-title":"Cancer Invest"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0047","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0022-5347(17)38957-7","article-title":"Percutaneous bacillus Calmette-Guerin perfusion of the upper urinary tract for carcinoma in situ","volume":"142","author":"Studer","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0048","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/01.ju.0000147747.89028.64","article-title":"Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation","volume":"173","author":"Yossepowitch","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0049","doi-asserted-by":"crossref","unstructured":"Liu Z., Ng J., Yuwono A., Lu Y., Tan Y.K. Which is best method for instillation of topical therapy to the upper urinary tract? an in vivo porcine study to evaluate three delivery methods. Int Braz J Urol n.d.; 43:1084\u201391. doi:10.1590\/S1677-5538.IBJU.2016.0258.","DOI":"10.1590\/s1677-5538.ibju.2016.0258"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0050","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.urology.2013.08.048","article-title":"Comparison of 3 upper tract anticarcinogenic agent delivery techniques in an Ex Vivo Porcine Model","volume":"82","author":"Pollard","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0051","doi-asserted-by":"crossref","unstructured":"Babjuk M., B\u00f6hle A., Burger M., Capoun O., Cohen D., Comp\u00e9rat E.M., et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol n.d.;71:447\u201361. doi:10.1016\/j.eururo.2016.05.041.","DOI":"10.1016\/j.eururo.2016.05.041"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0052","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.juro.2012.12.006","article-title":"Endoscopic versus laparoscopic management of noninvasive upper tract urothelial carcinoma: 20-year single center experience","volume":"189","author":"Cutress","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0053","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.urology.2012.12.059","article-title":"Comparative analysis of oncologic outcomes of partial ureterectomy vs radical nephroureterectomy in upper tract urothelial carcinoma","volume":"81","author":"Bagrodia","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2019.02.004_bib0054","doi-asserted-by":"crossref","first-page":"e1166","DOI":"10.1016\/j.juro.2018.03.097","article-title":"LBA25 non-surgical management of low grade upper tract urothelial cancer: an interim analysis of the International Multicenter Olympus Trial (NCT02793128)","volume":"199","author":"Kleinmann","year":"2018","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143919300572?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143919300572?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:15:15Z","timestamp":1761041715000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143919300572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1078143919300572"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2019.02.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2019.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}